Review



usp7 activity hbx 41108  (Tocris)


Bioz Verified Symbol Tocris is a verified supplier
Bioz Manufacturer Symbol Tocris manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Tocris usp7 activity hbx 41108
    Fig. 6. TGF-β impairs TCF7L2 protein stability via the UPS. (A) Representativewestern blots showing TCF7L2 protein levels after treatment with cycloheximide (CHX, 30 μg/ml) for different time periods (0, 3, 6, 9, 12 h) in C3H/10T1/2 cells. Ponceau was used as the loading control. (B) Quantification of three independent experiments showing TCF7L2 protein levels (as the mean±s.e.m. percentage of the 0 h level) after CHX treatment. (C) Representative western blots showing TCF7L2 protein levels after treatment with CHX for different time periods (0, 3, 6, 9 h) in wild-type muscle PDGFRα+ FAPs. (D) BioGRID interactome analysis of the human TCF7L2 protein. Black circles mark the protein–protein interactions between TCF7L2 and RNF4, RNF43, RNF138, NLK, UHRF2, UBE2I, UBE2L6, USP4, UBR5 and XIAP. (E) In silico prediction of TCF7L2 ubiquitination sites, showing the amino acid sequence of human TCF7L2 protein variant 1. Potential TCF7L2-ubiquitinated lysine residues were ranked and are shown in red. (F) Representative western blots showing TCF7L2 and CCN2 (CTGF) protein levels after TGF-β1 (1 ng/ml) and MG132 (15 μM) treatments (9 h). Tubulin was used as the loading control. (G) Quantification of TCF7L2 protein levels in the experiment described in F. n=6. ***P<0.001; **P<0.005; *P<0.05 (one-way ANOVA with Dunnett’s post-test). (H) Western blots representative of three independent experiments that evaluate total levels of TCF7L2 following <t>USP7</t> small-molecule inhibitor HBX 41108 (10 μM) and CHX treatments for different time periods (0, 4, 6, 8 h) in C3H/10T1/2 MSCs. Tubulin was used as the loading control and the ratio of TCF7L2 to tubulin signal is shown.
    Usp7 Activity Hbx 41108, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 19 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/usp7+activity+hbx+41108/HBX+41108/pm32434871-296-87-96
    Average 93 stars, based on 19 article reviews
    usp7 activity hbx 41108 - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "TGF-β-driven downregulation of the transcription factor TCF7L2 affects Wnt/β-catenin signaling in PDGFRα + fibroblasts."

    Article Title: TGF-β-driven downregulation of the transcription factor TCF7L2 affects Wnt/β-catenin signaling in PDGFRα + fibroblasts.

    Journal: Journal of cell science

    doi: 10.1242/jcs.242297

    Fig. 6. TGF-β impairs TCF7L2 protein stability via the UPS. (A) Representativewestern blots showing TCF7L2 protein levels after treatment with cycloheximide (CHX, 30 μg/ml) for different time periods (0, 3, 6, 9, 12 h) in C3H/10T1/2 cells. Ponceau was used as the loading control. (B) Quantification of three independent experiments showing TCF7L2 protein levels (as the mean±s.e.m. percentage of the 0 h level) after CHX treatment. (C) Representative western blots showing TCF7L2 protein levels after treatment with CHX for different time periods (0, 3, 6, 9 h) in wild-type muscle PDGFRα+ FAPs. (D) BioGRID interactome analysis of the human TCF7L2 protein. Black circles mark the protein–protein interactions between TCF7L2 and RNF4, RNF43, RNF138, NLK, UHRF2, UBE2I, UBE2L6, USP4, UBR5 and XIAP. (E) In silico prediction of TCF7L2 ubiquitination sites, showing the amino acid sequence of human TCF7L2 protein variant 1. Potential TCF7L2-ubiquitinated lysine residues were ranked and are shown in red. (F) Representative western blots showing TCF7L2 and CCN2 (CTGF) protein levels after TGF-β1 (1 ng/ml) and MG132 (15 μM) treatments (9 h). Tubulin was used as the loading control. (G) Quantification of TCF7L2 protein levels in the experiment described in F. n=6. ***P<0.001; **P<0.005; *P<0.05 (one-way ANOVA with Dunnett’s post-test). (H) Western blots representative of three independent experiments that evaluate total levels of TCF7L2 following USP7 small-molecule inhibitor HBX 41108 (10 μM) and CHX treatments for different time periods (0, 4, 6, 8 h) in C3H/10T1/2 MSCs. Tubulin was used as the loading control and the ratio of TCF7L2 to tubulin signal is shown.
    Figure Legend Snippet: Fig. 6. TGF-β impairs TCF7L2 protein stability via the UPS. (A) Representativewestern blots showing TCF7L2 protein levels after treatment with cycloheximide (CHX, 30 μg/ml) for different time periods (0, 3, 6, 9, 12 h) in C3H/10T1/2 cells. Ponceau was used as the loading control. (B) Quantification of three independent experiments showing TCF7L2 protein levels (as the mean±s.e.m. percentage of the 0 h level) after CHX treatment. (C) Representative western blots showing TCF7L2 protein levels after treatment with CHX for different time periods (0, 3, 6, 9 h) in wild-type muscle PDGFRα+ FAPs. (D) BioGRID interactome analysis of the human TCF7L2 protein. Black circles mark the protein–protein interactions between TCF7L2 and RNF4, RNF43, RNF138, NLK, UHRF2, UBE2I, UBE2L6, USP4, UBR5 and XIAP. (E) In silico prediction of TCF7L2 ubiquitination sites, showing the amino acid sequence of human TCF7L2 protein variant 1. Potential TCF7L2-ubiquitinated lysine residues were ranked and are shown in red. (F) Representative western blots showing TCF7L2 and CCN2 (CTGF) protein levels after TGF-β1 (1 ng/ml) and MG132 (15 μM) treatments (9 h). Tubulin was used as the loading control. (G) Quantification of TCF7L2 protein levels in the experiment described in F. n=6. ***P<0.001; **P<0.005; *P<0.05 (one-way ANOVA with Dunnett’s post-test). (H) Western blots representative of three independent experiments that evaluate total levels of TCF7L2 following USP7 small-molecule inhibitor HBX 41108 (10 μM) and CHX treatments for different time periods (0, 4, 6, 8 h) in C3H/10T1/2 MSCs. Tubulin was used as the loading control and the ratio of TCF7L2 to tubulin signal is shown.

    Techniques Used: Control, Western Blot, Protein-Protein interactions, In Silico, Ubiquitin Proteomics, Sequencing, Variant Assay

    Related Articles

    Activity Assay:

    Article Title: TGF-β-driven downregulation of the transcription factor TCF7L2 affects Wnt/β-catenin signaling in PDGFRα + fibroblasts.
    Article Snippet: All flow cytometry data were analyzed using FlowJo 10.5.3v. .. The TGFBR1 inhibitor SB525334 (used at 5 μM; S8822, Sigma-Aldrich), p38 MAPK inhibitor SB203580 (used at 20 μM; 5633, Cell Signaling Technology), MEK1/2 inhibitor (used to subsequently inhibit ERK1/2 kinases) UO126 (used at 10 μM; 9903, Cell Signaling Technology), SMAD3 inhibitor SIS3 (used at 6 μM; 1009104-85-1, Merck Calbiochem), JNK activity inhibitor SB600125 (used at 20 μM; Cell Signaling Technology), trichostatin A (used at 10 μM; T8552, Sigma-Aldrich; kindly provided by Dr Martín Montecino, Instituto de Ciencias Biomédicas, Universidad Andrés Bello, Santiago, Chile) and the inhibitor of USP7 activity HBX 41108 (used at 10 μM; 4285; Tocris; kindly provided by Dr Hugo Olguín, Pontificia Universidad Católica de Chile, Santiago, Chile) were all diluted in DMSO. ..

    Article Title: TGF-β-driven downregulation of the Wnt/β-Catenin transcription factor TCF7L2/TCF4 in PDGFRα + fibroblasts
    Article Snippet: All flow cytometry data were analyzed using FlowJo 10.5.3v. .. The TGFBR1 inhibitor SB525334 (used at 5 μM; S8822, Sigma-Aldrich), p38 MAPK SB203580 inhibitor (used at 20 μM; 5633, Cell Signaling Technology), PI3K/AKT inhibitor LY294002 (used at 10 μM; 440202, Merck-Calbiochem), the inhibitor of MEK1/2/ERK1/2 kinases UO126 (used at 10 μM; 9903, Cell Signaling Technology), Smad3 inhibitor SIS3 (used at 6 μM; 1009104-85-1, Merck-Calbiochem), the inhibitor of JNK activity SB600125 (used at 20 μM; Cell Signaling Technology), trichostatin A (TSA) (used at 10 μM; T8552, Sigma-Aldrich), and the inhibitor of USP7 activity HBX 41108 (used at 10uM; 4285; Tocris) were all diluted in DMSO. ..



    Similar Products

    usp7 activity hbx 41108  (Tocris)
    93
    Tocris usp7 activity hbx 41108
    Fig. 6. TGF-β impairs TCF7L2 protein stability via the UPS. (A) Representativewestern blots showing TCF7L2 protein levels after treatment with cycloheximide (CHX, 30 μg/ml) for different time periods (0, 3, 6, 9, 12 h) in C3H/10T1/2 cells. Ponceau was used as the loading control. (B) Quantification of three independent experiments showing TCF7L2 protein levels (as the mean±s.e.m. percentage of the 0 h level) after CHX treatment. (C) Representative western blots showing TCF7L2 protein levels after treatment with CHX for different time periods (0, 3, 6, 9 h) in wild-type muscle PDGFRα+ FAPs. (D) BioGRID interactome analysis of the human TCF7L2 protein. Black circles mark the protein–protein interactions between TCF7L2 and RNF4, RNF43, RNF138, NLK, UHRF2, UBE2I, UBE2L6, USP4, UBR5 and XIAP. (E) In silico prediction of TCF7L2 ubiquitination sites, showing the amino acid sequence of human TCF7L2 protein variant 1. Potential TCF7L2-ubiquitinated lysine residues were ranked and are shown in red. (F) Representative western blots showing TCF7L2 and CCN2 (CTGF) protein levels after TGF-β1 (1 ng/ml) and MG132 (15 μM) treatments (9 h). Tubulin was used as the loading control. (G) Quantification of TCF7L2 protein levels in the experiment described in F. n=6. ***P<0.001; **P<0.005; *P<0.05 (one-way ANOVA with Dunnett’s post-test). (H) Western blots representative of three independent experiments that evaluate total levels of TCF7L2 following <t>USP7</t> small-molecule inhibitor HBX 41108 (10 μM) and CHX treatments for different time periods (0, 4, 6, 8 h) in C3H/10T1/2 MSCs. Tubulin was used as the loading control and the ratio of TCF7L2 to tubulin signal is shown.
    Usp7 Activity Hbx 41108, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/usp7+activity+hbx+41108/HBX+41108/pm32434871-296-87-96
    Average 93 stars, based on 1 article reviews
    usp7 activity hbx 41108 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    inhibitor of usp7 activity hbx 41108  (Tocris)
    90
    Tocris inhibitor of usp7 activity hbx 41108
    Fig. 6. TGF-β impairs TCF7L2 protein stability via the UPS. (A) Representativewestern blots showing TCF7L2 protein levels after treatment with cycloheximide (CHX, 30 μg/ml) for different time periods (0, 3, 6, 9, 12 h) in C3H/10T1/2 cells. Ponceau was used as the loading control. (B) Quantification of three independent experiments showing TCF7L2 protein levels (as the mean±s.e.m. percentage of the 0 h level) after CHX treatment. (C) Representative western blots showing TCF7L2 protein levels after treatment with CHX for different time periods (0, 3, 6, 9 h) in wild-type muscle PDGFRα+ FAPs. (D) BioGRID interactome analysis of the human TCF7L2 protein. Black circles mark the protein–protein interactions between TCF7L2 and RNF4, RNF43, RNF138, NLK, UHRF2, UBE2I, UBE2L6, USP4, UBR5 and XIAP. (E) In silico prediction of TCF7L2 ubiquitination sites, showing the amino acid sequence of human TCF7L2 protein variant 1. Potential TCF7L2-ubiquitinated lysine residues were ranked and are shown in red. (F) Representative western blots showing TCF7L2 and CCN2 (CTGF) protein levels after TGF-β1 (1 ng/ml) and MG132 (15 μM) treatments (9 h). Tubulin was used as the loading control. (G) Quantification of TCF7L2 protein levels in the experiment described in F. n=6. ***P<0.001; **P<0.005; *P<0.05 (one-way ANOVA with Dunnett’s post-test). (H) Western blots representative of three independent experiments that evaluate total levels of TCF7L2 following <t>USP7</t> small-molecule inhibitor HBX 41108 (10 μM) and CHX treatments for different time periods (0, 4, 6, 8 h) in C3H/10T1/2 MSCs. Tubulin was used as the loading control and the ratio of TCF7L2 to tubulin signal is shown.
    Inhibitor Of Usp7 Activity Hbx 41108, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/usp7+activity+hbx+41108/hbx41108/pm32434871-296-85-96
    Average 90 stars, based on 1 article reviews
    inhibitor of usp7 activity hbx 41108 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 6. TGF-β impairs TCF7L2 protein stability via the UPS. (A) Representativewestern blots showing TCF7L2 protein levels after treatment with cycloheximide (CHX, 30 μg/ml) for different time periods (0, 3, 6, 9, 12 h) in C3H/10T1/2 cells. Ponceau was used as the loading control. (B) Quantification of three independent experiments showing TCF7L2 protein levels (as the mean±s.e.m. percentage of the 0 h level) after CHX treatment. (C) Representative western blots showing TCF7L2 protein levels after treatment with CHX for different time periods (0, 3, 6, 9 h) in wild-type muscle PDGFRα+ FAPs. (D) BioGRID interactome analysis of the human TCF7L2 protein. Black circles mark the protein–protein interactions between TCF7L2 and RNF4, RNF43, RNF138, NLK, UHRF2, UBE2I, UBE2L6, USP4, UBR5 and XIAP. (E) In silico prediction of TCF7L2 ubiquitination sites, showing the amino acid sequence of human TCF7L2 protein variant 1. Potential TCF7L2-ubiquitinated lysine residues were ranked and are shown in red. (F) Representative western blots showing TCF7L2 and CCN2 (CTGF) protein levels after TGF-β1 (1 ng/ml) and MG132 (15 μM) treatments (9 h). Tubulin was used as the loading control. (G) Quantification of TCF7L2 protein levels in the experiment described in F. n=6. ***P<0.001; **P<0.005; *P<0.05 (one-way ANOVA with Dunnett’s post-test). (H) Western blots representative of three independent experiments that evaluate total levels of TCF7L2 following USP7 small-molecule inhibitor HBX 41108 (10 μM) and CHX treatments for different time periods (0, 4, 6, 8 h) in C3H/10T1/2 MSCs. Tubulin was used as the loading control and the ratio of TCF7L2 to tubulin signal is shown.

    Journal: Journal of cell science

    Article Title: TGF-β-driven downregulation of the transcription factor TCF7L2 affects Wnt/β-catenin signaling in PDGFRα + fibroblasts.

    doi: 10.1242/jcs.242297

    Figure Lengend Snippet: Fig. 6. TGF-β impairs TCF7L2 protein stability via the UPS. (A) Representativewestern blots showing TCF7L2 protein levels after treatment with cycloheximide (CHX, 30 μg/ml) for different time periods (0, 3, 6, 9, 12 h) in C3H/10T1/2 cells. Ponceau was used as the loading control. (B) Quantification of three independent experiments showing TCF7L2 protein levels (as the mean±s.e.m. percentage of the 0 h level) after CHX treatment. (C) Representative western blots showing TCF7L2 protein levels after treatment with CHX for different time periods (0, 3, 6, 9 h) in wild-type muscle PDGFRα+ FAPs. (D) BioGRID interactome analysis of the human TCF7L2 protein. Black circles mark the protein–protein interactions between TCF7L2 and RNF4, RNF43, RNF138, NLK, UHRF2, UBE2I, UBE2L6, USP4, UBR5 and XIAP. (E) In silico prediction of TCF7L2 ubiquitination sites, showing the amino acid sequence of human TCF7L2 protein variant 1. Potential TCF7L2-ubiquitinated lysine residues were ranked and are shown in red. (F) Representative western blots showing TCF7L2 and CCN2 (CTGF) protein levels after TGF-β1 (1 ng/ml) and MG132 (15 μM) treatments (9 h). Tubulin was used as the loading control. (G) Quantification of TCF7L2 protein levels in the experiment described in F. n=6. ***P<0.001; **P<0.005; *P<0.05 (one-way ANOVA with Dunnett’s post-test). (H) Western blots representative of three independent experiments that evaluate total levels of TCF7L2 following USP7 small-molecule inhibitor HBX 41108 (10 μM) and CHX treatments for different time periods (0, 4, 6, 8 h) in C3H/10T1/2 MSCs. Tubulin was used as the loading control and the ratio of TCF7L2 to tubulin signal is shown.

    Article Snippet: The TGFBR1 inhibitor SB525334 (used at 5 μM; S8822, Sigma-Aldrich), p38 MAPK inhibitor SB203580 (used at 20 μM; 5633, Cell Signaling Technology), MEK1/2 inhibitor (used to subsequently inhibit ERK1/2 kinases) UO126 (used at 10 μM; 9903, Cell Signaling Technology), SMAD3 inhibitor SIS3 (used at 6 μM; 1009104-85-1, Merck Calbiochem), JNK activity inhibitor SB600125 (used at 20 μM; Cell Signaling Technology), trichostatin A (used at 10 μM; T8552, Sigma-Aldrich; kindly provided by Dr Martín Montecino, Instituto de Ciencias Biomédicas, Universidad Andrés Bello, Santiago, Chile) and the inhibitor of USP7 activity HBX 41108 (used at 10 μM; 4285; Tocris; kindly provided by Dr Hugo Olguín, Pontificia Universidad Católica de Chile, Santiago, Chile) were all diluted in DMSO.

    Techniques: Control, Western Blot, Protein-Protein interactions, In Silico, Ubiquitin Proteomics, Sequencing, Variant Assay